Egret Therapeutics is a biopharmaceutical company in the phase of clinical trials. The organization is dedicated to creating remedies to tackle areas of unmet medical necessity in brain-related disorders. Egret Therapeutics, a developmental-stage biopharmaceutical firm focusing on creating groundbreaking treatments for brain-related ailments, has announced today that the Investigational New Drug (IND) application for EGT 101, intended for the management of Delayed Cerebral Ischemia (DCI) after aneurysmal subarachnoid hemorrhage, has been authorized by the U.S. Food and Drug Administration (FDA).